Clinical Trials Logo

Gentamicin Ototoxicity clinical trials

View clinical trials related to Gentamicin Ototoxicity.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05676944 Recruiting - Vestibular Diseases Clinical Trials

Vestibular Implantation in Older Adults

Start date: April 11, 2023
Phase: N/A
Study type: Interventional

Although cochlear implants can restore hearing to individuals who have lost cochlear hair cell function, there is no widely available, adequately effective treatment for individuals suffering chronic imbalance, postural instability and unsteady vision due to bilateral vestibular hypofunction. Prior research has demonstrated that electrical stimulation of the vestibular nerve via a chronically implanted multichannel vestibular implant can partially restore vestibular reflexes that normally maintain steady posture and vision; improve performance on objective measures of postural stability and gait; and improve patient-reported disability and health-related quality of life. This single-arm open-label study extends that research to evaluate outcomes for up to fifteen older adults (age 65-90 years at time of enrollment) with ototoxic or non-ototoxic bilateral vestibular hypofunction.

NCT ID: NCT05674786 Recruiting - Vestibular Diseases Clinical Trials

Vestibular Implantation to Treat Adult-Onset Bilateral Vestibular Hypofunction

Start date: February 28, 2023
Phase: N/A
Study type: Interventional

Although cochlear implants can restore hearing to individuals who have lost cochlear hair cell function, there is no widely available, adequately effective treatment for individuals suffering chronic imbalance, postural instability and unsteady vision due to bilateral vestibular hypofunction. Prior research focused on ototoxic cases has demonstrated that electrical stimulation of the vestibular nerve via a chronically implanted multichannel vestibular implant can partially restore vestibular reflexes that normally maintain steady posture and vision; improve performance on objective measures of postural stability and gait; and improve patient-reported disability and health-related quality of life. This single-arm open-label study extends that research to evaluate outcomes for up to 8 individuals with non-ototoxic bilateral vestibular hypofunction, yielding a total of fifteen adults (age 22-90 years at time of enrollment) divided as equally as possible between ototoxic and non-ototoxic cases.